Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on discovering, developing, and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant, indicating that the FDA could not determine a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on December 31, 2025 [3].